- Trials with a EudraCT protocol (144)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
144 result(s) found for: Benign neoplasms gastrointestinal.
Displaying page 1 of 8.
| EudraCT Number: 2020-004624-41 | Sponsor Protocol Number: 24092020 | Start Date*: 2021-07-07 | ||||||||||||||||
| Sponsor Name:Zealand University Hospital | ||||||||||||||||||
| Full Title: Calcium Electroporation for Malignant GI Bleeding – a randomized controlled trial | ||||||||||||||||||
| Medical condition: Malignant gastrointestinal bleeding | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-000551-10 | Sponsor Protocol Number: DoGE01 | Start Date*: 2009-03-19 | ||||||||||||||||
| Sponsor Name:Institut Jules Bordet | ||||||||||||||||||
| Full Title: Randomised Phase II study of biweekly versus fractionated triweekly combination Taxotere-Cisplatin-5FU in advanced gastric and gastro-esophageal junction cancer | ||||||||||||||||||
| Medical condition: Advanced gastric and oesogastric junction adenocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-017957-37 | Sponsor Protocol Number: BAY73-4506/14874 | Start Date*: 2010-12-14 | ||||||||||||||||
| Sponsor Name:Bayer HealthCare AG | ||||||||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gas... | ||||||||||||||||||
| Medical condition: Metastatic and /or unresectable gastrointestinal tumors (GIST) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) FI (Completed) NL (Completed) DE (Completed) GB (Completed) AT (Completed) FR (Completed) ES (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-001298-42 | Sponsor Protocol Number: 1321 | Start Date*: 2016-01-19 | |||||||||||||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||||||||||||
| Full Title: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST) | |||||||||||||||||||||||
| Medical condition: unresectable metastatic GIST | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: SK (Completed) ES (Completed) NO (Completed) FI (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) DK (Prematurely Ended) IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2011-001725-24 | Sponsor Protocol Number: CTKI258AIC02 | Start Date*: 2011-10-03 | |||||||||||
| Sponsor Name:Novartis Pharma Services | |||||||||||||
| Full Title: DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib | |||||||||||||
| Medical condition: Unresectable, metastatic or recurrent gastrointestinal stromal tumor (GIST) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) ES (Completed) FI (Completed) IT (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005751-21 | Sponsor Protocol Number: BLU-285-1408 | Start Date*: 2021-04-16 | |||||||||||||||||||||
| Sponsor Name:Blueprint Medicines | |||||||||||||||||||||||
| Full Title: Open-Label Extension Study to Evaluate the Safety of Long-Term Treatment with Avapritinib for Patients Previously Involved in an Avapritinib Study | |||||||||||||||||||||||
| Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2016-003774-40 | Sponsor Protocol Number: TheStopGISTtrial | Start Date*: 2016-11-09 | |||||||||||
| Sponsor Name:Oslo University Hospital | |||||||||||||
| Full Title: Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment | |||||||||||||
| Medical condition: Gastrointestinal stromal tumour (GIST) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NO (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-000357-35 | Sponsor Protocol Number: CAMN107DDE05 | Start Date*: 2008-11-04 | |||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||
| Full Title: An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib | |||||||||||||
| Medical condition: metastatic or unresectable gastrointestinal stromal tumor in patients resistant to imatinib or sunitinib | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Completed) GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-001547-43 | Sponsor Protocol Number: ET19-075 | Start Date*: 2022-01-18 | |||||||||||
| Sponsor Name:Centre Léon Bérard | |||||||||||||
| Full Title: ATEZOGIST – A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib resumption alone in patients with unresectabl... | |||||||||||||
| Medical condition: Unresectable locally advanced or metastatic gastrointestinal stromal tumors (GIST) after failure of standard treatments | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-022713-26 | Sponsor Protocol Number: CAMN107DDE12 | Start Date*: 2011-03-30 | |||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||
| Full Title: Localized gastrointestinal stromal tumors (GIST): an exploratory open-label, multicenter, single-arm phase II study to evaluate the efficacy of 2 years of adjuvant nilotinib treatment following at ... | |||||||||||||
| Medical condition: localized gastrointestinal stromal tumors (GIST) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-022560-12 | Sponsor Protocol Number: IMCLCP15-1008 | Start Date*: 2011-09-28 | |||||||||||
| Sponsor Name:ImClone LLC | |||||||||||||
| Full Title: A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients with Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST) | |||||||||||||
| Medical condition: Gastrointestinal Stromal Tumors (GIST) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) NL (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-001790-41 | Sponsor Protocol Number: AB11002 | Start Date*: 2013-04-10 | |||||||||||
| Sponsor Name:AB Science | |||||||||||||
| Full Title: A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointesti... | |||||||||||||
| Medical condition: Gastrointestinal stromal tumor resistant to imatinib | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) ES (Ongoing) NL (Ongoing) DE (Prohibited by CA) BE (Prematurely Ended) AT (Ongoing) GB (GB - no longer in EU/EEA) GR (Prematurely Ended) IT (Suspended by CA) CY (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-001093-11 | Sponsor Protocol Number: A6181030 | Start Date*: 2004-12-24 | |||||||||||
| Sponsor Name:Pfizer Global Research and Development | |||||||||||||
| Full Title: A Treatment Protocol for Patients Continuing from a Prior SU011248 Protocol | |||||||||||||
| Medical condition: This is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) ES (Prematurely Ended) NL (Completed) SE (Completed) GR (Prematurely Ended) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002285-23 | Sponsor Protocol Number: POETIG | Start Date*: 2017-01-18 | |||||||||||
| Sponsor Name:Universitaetsklinikum Essen | |||||||||||||
| Full Title: Phase 2 trial of ponatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure or intolerance of prior therapy with imatinib (POETIG trial – POna... | |||||||||||||
| Medical condition: gastrointestinal stromal tumor (GIST) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-001810-16 | Sponsor Protocol Number: 62024 | Start Date*: 2004-11-25 | |||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
| Full Title: Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versu... | |||||||||||||
| Medical condition: Gastrointestinal stromal tumors (GIST) are mesenchymal neoplasms usually arising from the gastrointestinal wall. Pathologically,they present with spindle cells in most cases. Immunohistochemically... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) DK (Completed) GB (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-001860-27 | Sponsor Protocol Number: A6181036 | Start Date*: 2007-09-12 | |||||||||||
| Sponsor Name:Pfizer Limited | |||||||||||||
| Full Title: A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE | |||||||||||||
| Medical condition: Patients with Gastrointestinal Stromal Tumor who are Refractory to Standard Therapy and May Derive Benefit for Treatment with SU011248 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) SK (Completed) HU (Completed) FI (Completed) DK (Completed) AT (Prematurely Ended) SE (Completed) ES (Prematurely Ended) GR (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003497-14 | Sponsor Protocol Number: BLU-285-1303 | Start Date*: 2018-04-23 | ||||||||||||||||
| Sponsor Name:Blueprint Medicines Corporation | ||||||||||||||||||
| Full Title: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | ||||||||||||||||||
| Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) SE (Completed) HU (Completed) DE (Completed) NL (Completed) AT (Completed) ES (Completed) BE (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2006-004309-24 | Sponsor Protocol Number: A6181112 | Start Date*: 2007-05-02 | |||||||||||
| Sponsor Name:Pfizer Inc., East 42nd Street, New York, NY 10017 | |||||||||||||
| Full Title: A PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT®) 37.5 MG DAILY VS IMATINIB MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS... | |||||||||||||
| Medical condition: TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Completed) ES (Completed) FR (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-000973-40 | Sponsor Protocol Number: AB04030 | Start Date*: 2008-12-18 | |||||||||||
| Sponsor Name:AB SCIENCE | |||||||||||||
| Full Title: A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in... | |||||||||||||
| Medical condition: gastro-intestinal stromal tumour | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) HU (Prematurely Ended) DE (Prohibited by CA) AT (Completed) BE (Prematurely Ended) ES (Prematurely Ended) NL (Temporarily Halted) GB (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-005175-27 | Sponsor Protocol Number: IB2017-01 | Start Date*: 2018-03-14 | ||||||||||||||||||||||||||
| Sponsor Name:Institut Bergonié | ||||||||||||||||||||||||||||
| Full Title: A phase I/II study of Regorafenib plus Avelumab in digestive tumors | ||||||||||||||||||||||||||||
| Medical condition: Adult patients with advanced or metastatic digestive solid tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.